ConcertAI Appoints Michael Myshrall as Chief Financial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the appointment of Michael Myshrall as chief financial officer (CFO). Myshrall brings over two decades of financial leadership experience in SaaS, artificial intelligence (AI) and technology sectors, positioning him to help accelerate ConcertAI's continued expansion and innovation in AI-powered clinical research and care.

Myshrall joins ConcertAI following a distinguished career leading financial operations for high-growth technology companies. Most recently, he served as CFO at Afiniti, a leader in customer experience AI software, where he led an international finance organization and helped navigate a complex financial recapitalization of the business.

Previously, Myshrall served as CFO for NASDAQ-listed cybersecurity company Cyren, where he raised over $100 million in equity and debt capital, including a majority sale to private equity firm Warburg Pincus. He was also CFO for PrimePay, a private-equity-backed human capital management software company. His expertise spans the full spectrum of SaaS business models, recurring revenue optimization and the financial metrics critical to scaling AI-driven healthcare technologies.

"Mike’s proven track record of driving financial excellence and operational scale makes him the ideal leader to guide ConcertAI through our next phase of growth," said Eron Kelly, Chief Executive Officer of ConcertAI. "His deep understanding of SaaS models, combined with his experience in AI and technology sectors, aligns perfectly with our mission to accelerate breakthroughs in life sciences and healthcare through innovative AI solutions."

Myshrall's appointment comes as ConcertAI continues to expand its comprehensive platform that unifies real-world data, AI innovation, and clinical expertise. The company's integrated solutions span from drug discovery to clinical trials to patient care delivery, serving major pharmaceutical companies and leading healthcare institutions worldwide.

A Harvard Business School Master of Business Administration graduate and former management consultant, Myshrall has led mergers and acquisitions, capital raising efforts and complex financial transactions throughout his career. His experience includes successful public offerings, private equity investments and the implementation of advanced financial planning and analysis systems optimized for SaaS and AI business models.

About ConcertAI

ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Mass., ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.